Atossa Genetics Inc. (ATOS)
Symbol Info
Listed Symbol ATOS
Name Atossa Genetics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-13.99
Price Info
21 Day Moving Average $1.8547
21 Day EMA $1.831830
50 Day Moving Average $1.9890
50 Day EMA $1.953900
200 Day EMA $2.218190
200 Day Moving Average 2.214780
52 Week High $7.39
52 Week Low $0.80
52 Week Change $11.949700
Alpha -0.048819
Beta 3.2863
Standard Deviation 0.399476
R2 0.079812
Periods 60
Share Information
10 Day Average Volume 215,841
20 Day Average Volume 166,542
30 Day Average Volume 157,031
50 Day Average Volume 132,570
Outstanding Shares 9,129,563
Float Shares 8,580,455
Percent Float 93.99%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 31
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 67,034
Institute Holdings Percent 3.300000
Institute Sold Previous 3 Months 95,859
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 6.00%
Insider Sold Previous 3 Months -
Insiders Shares Owned 549,108
Price Change
7 Day Price Change $0.0899999
7 Day Percent Change 5.33%
21 Day Price Change $-0.25
21 Day Percent Change -12.32%
30 Day Price Change $-0.23
30 Day Percent Change -11.44%
Month To Date Price Change $-0.18
Month To Date Percent -9.18%
90 Day Price Change $-0.315
90 Day Percent Change -15.04%
Quarter To Date $-0.18
Quarter To Date Percent -9.18%
180 Day Price Change $-0.76
180 Day Percent Change -29.92%
200 Day Price Change $-1.8
200 Day Percent Change -50.28%
Year To Date $0.760000
Year To Date Percent 74.51%
Profile
Description Atossa Genetics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcatheters which delivers a number of therapeutics to the ducts in the breast, the site of the majority of early breast cancers and fulvestrant Delivered through microcatheters which delivers fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition, the company involves in the process of evaluating additional potential indications of endoxifen and other therapeutic candidates to treat breast conditions, including breast cancer.
Details
Issue Type CS
Market Cap $16,250,622
Sec Type EQS
Auditor BDO USA, LLP
Total Shares Outstanding 9,129,563
CEO Steven C. Quay
Employees 6
Last Audit UQ
Classification
CIK 0001488039
Industry Biotechnology
Sector Healthcare
NAICS In-Vitro Diagnostic Substance Manufacturing(325413)
Info
Address 107 Spring Street
Seattle, WA 98104
Website https://www.atossagenetics.com
Facisimile +1 206 902-9658
Telephone +1 206 325-6068
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $1,587,238
Price To Sales -
Price To Free Cash -2.2
PE High Last 5 Years -
Price To Book 1.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.0
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 17.8
Leverage Ratio 1.2
Quick Ratio 16.9
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -95.06
Return On Equity -109.87
Return On Capital -109.32
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ATOS
Atossa Gen..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.